Butterfly Network Partners with Bridge Neurotech on Ultrasound-Based Brain-Computer Interface

What happened

Butterfly Network announced a multi-year partnership with Bridge Neurotech to develop a non-invasive brain-computer interface using its ultrasound technology. This collaboration explores a novel, long-horizon application beyond the company's current point-of-care ultrasound markets. The deal does not alter near-term financials, as Butterfly remains focused on enterprise software and core ultrasound growth, with 2024 revenue of $82.1 million and still loss-making. It adds optionality but carries high uncertainty, since BCI via ultrasound is early-stage and unlikely to generate revenue for years. Overall, the partnership is a positive signal of platform versatility but should be viewed as a speculative growth option within the existing HOLD thesis.

Implication

The partnership with Bridge Neurotech does not change our HOLD recommendation on Butterfly Network. While it could eventually open a new market for ultrasound-based brain-computer interfaces, the project is multi-year and highly speculative, with no near-term revenue impact. Investors should continue to focus on core execution: enterprise software adoption, gross margin expansion, and progress toward cash flow breakeven. The additional optionality may support a slightly higher multiple if the market perceives platform extensibility, but we view it as a low-probability, high-impact scenario at this stage. We would require evidence of meaningful progress or funding commitments before incorporating BCI into our valuation.

Thesis delta

Our HOLD thesis is unchanged. The Bridge Neurotech collaboration adds a speculative long-term option but does not affect our base case, which remains dependent on enterprise software and core ultrasound growth. We maintain a neutral stance until clear catalysts emerge.